Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements.

Tytuł:
Development of an intraoperative breast cancer margin assessment method using quantitative fluorescence measurements.
Autorzy:
Ueo H; Ueo Breast Cancer Hospital, 1-3-5 Futamatamachi, Oita, 870-0887, Japan. .; Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan. .
Minoura I; Goryo Chemical Inc., Kita 8 Nishi 18-35-100, Chuo-ku, Sapporo, 060-0008, Japan. .
Ueo H; Ueo Breast Cancer Hospital, 1-3-5 Futamatamachi, Oita, 870-0887, Japan.
Gamachi A; Department of Pathology, Almeida Memorial Hospital, Oita, 870-1195, Japan.
Kai Y; Ueo Breast Cancer Hospital, 1-3-5 Futamatamachi, Oita, 870-0887, Japan.
Kubota Y; Ueo Breast Cancer Hospital, 1-3-5 Futamatamachi, Oita, 870-0887, Japan.
Doi T; Breast Cancer Center, Shonan Memorial Hospital, Kamakura, 248-0027, Japan.
Yamaguchi M; Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, 830-0013, Japan.
Yamashita T; Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
Tsuda H; Department of Basic Pathology, National Defense Medical College, Tokorozawa, 359-8513, Japan.
Moriya T; Department of Pathology, Kawasaki Medical School, Kurashiki, 701-0192, Japan.
Yamaguchi R; Department of Pathology and Laboratory Medicine, Kurume University Medical Center, Kurume, 839-0863, Japan.
Kozuka Y; Department of Pathology, Mie University Hospital, Tsu, 514-8507, Japan.
Sasaki T; Department of Next-Generation Pathology Information and Networking, Faculty of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
Masuda T; Department of Surgery, Kyushu University Beppu Hospital, Beppu, 874-0838, Japan.
Urano Y; Graduate School of Medicine and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, 113-0033, Japan.
Mori M; Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Mimori K; Department of Surgery, Kyushu University Beppu Hospital, Beppu, 874-0838, Japan. .
Źródło:
Scientific reports [Sci Rep] 2022 May 20; Vol. 12 (1), pp. 8520. Date of Electronic Publication: 2022 May 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/surgery
Margins of Excision*
Female ; Fluorescent Dyes ; Humans ; Mastectomy, Segmental ; Reproducibility of Results ; gamma-Glutamyltransferase
References:
Sci Rep. 2016 Jun 09;6:27525. (PMID: 27277343)
Genome Res. 2005 Oct;15(10):1388-92. (PMID: 16204192)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Adv Sci (Weinh). 2018 Nov 27;6(2):1801479. (PMID: 30693189)
N Engl J Med. 2002 Oct 17;347(16):1233-41. (PMID: 12393820)
Ann Surg. 2021 Jul 1;274(1):97-106. (PMID: 33351457)
Sci Rep. 2015 Jul 13;5:12080. (PMID: 26165706)
Cancer. 2000 Apr 1;88(7):1643-9. (PMID: 10738223)
ACS Cent Sci. 2020 Dec 23;6(12):2217-2227. (PMID: 33376783)
Arch Pathol Lab Med. 2009 Jul;133(7):1135-8. (PMID: 19642740)
Jpn J Clin Oncol. 2010 Jun;40(6):513-20. (PMID: 20189973)
Cancer. 2015 Jan 15;121(2):169-78. (PMID: 25132313)
Br J Surg. 2021 Oct 23;108(10):e340-e342. (PMID: 34428279)
Ann Surg Oncol. 2012 Oct;19(10):3236-45. (PMID: 22847119)
Front Oncol. 2017 Aug 28;7:192. (PMID: 28894698)
Lancet Oncol. 2006 May;7(5):392-401. (PMID: 16648043)
Sci Transl Med. 2011 Nov 23;3(110):110ra119. (PMID: 22116934)
Cancer. 2004 May 1;100(9):1823-32. (PMID: 15112262)
Cancer. 2009 Jun 1;115(11):2491-504. (PMID: 19326450)
Biophysics (Nagoya-shi). 2005 Apr 21;1:25-31. (PMID: 27857550)
Acta Inform Med. 2013 Mar;21(1):16-9. (PMID: 23572855)
JAMA Surg. 2015 Aug;150(8):739-45. (PMID: 26039049)
J Am Chem Soc. 2013 Jan 9;135(1):409-14. (PMID: 23205758)
Breast Cancer (Auckl). 2016 Dec 08;10:205-210. (PMID: 27980416)
Curr Opin Chem Biol. 2016 Aug;33:9-15. (PMID: 27100047)
Breast Cancer. 2020 May;27(3):309-321. (PMID: 32152792)
Virchows Arch. 2021 Feb;478(2):335-341. (PMID: 32719890)
Nat Rev Clin Oncol. 2022 Jan;19(1):9-22. (PMID: 34493858)
Clin Cancer Res. 2021 Jul 15;27(14):3936-3947. (PMID: 34031057)
Eur J Cancer. 2010 Dec;46(18):3219-32. (PMID: 20817513)
Substance Nomenclature:
0 (Fluorescent Dyes)
EC 2.3.2.2 (gamma-Glutamyltransferase)
Entry Date(s):
Date Created: 20220520 Date Completed: 20220524 Latest Revision: 20220715
Update Code:
20240105
PubMed Central ID:
PMC9122917
DOI:
10.1038/s41598-022-12614-6
PMID:
35595810
Czasopismo naukowe
Breast-conserving surgery has become the preferred treatment method for breast cancer. Surgical margin assessment is performed during surgery, as it can reduce local recurrence in the preserved breast. Development of reliable and lower-cost ex vivo cancer detection methods would offer several benefits for patient care. Here, a practical and quantitative evaluation method for the ex vivo fluorescent diagnosis of breast lesions was developed and confirmed through a three-step clinical study. Gamma-glutamyl-hydroxymethyl rhodamine green (gGlu-HMRG) has been reported to generate fluorescence in breast lesions. Using this probe, we constructed a reliable and reproducible procedure for the quantitative evaluation of fluorescence levels. We evaluated the reliability of the method by considering reproducibility, temperature sensitivity, and the effects of other clinicopathological factors. The results suggest that the fluorescence increase of gGlu-HMRG is a good indicator of the malignancy of breast lesions. However, the distributions overlapped. A 5 min reaction with this probe could be used to distinguish at least part of the normal breast tissue. This method did not affect the final pathological examination. In summary, our results indicate that the methods developed in this study may serve as a feasible intraoperative negative-margin assessment tool during breast-conserving surgery.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies